Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

DURECT Corporation (DRRX)

6.36   -0.13 (-2%) 05-31 11:43
Open: 6.5 Pre. Close: 6.49
High: 6.7385 Low: 6.26
Volume: 21,514 Market Cap: 156(M)

Technical analysis

as of: 2023-05-31 11:16:12 AM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 8.71     One year: 10.17
Support: Support1: 5.35    Support2: 4.05
Resistance: Resistance1: 7.46    Resistance2: 8.71
Pivot: 5.69
Moving Average: MA(5): 6.17     MA(20): 5.35
MA(100): 5.22     MA(250): 5.32
MACD: MACD(12,26): 0.4     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 63     %D(3): 59.9
RSI: RSI(14): 64.6
52-week: High: 9.69  Low: 3.17
Average Vol(K): 3-Month: 119 (K)  10-Days: 163 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ DRRX ] has closed below upper band by 24.4%. Bollinger Bands are 49.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.72 - 6.75 6.75 - 6.78
Low: 6.03 - 6.06 6.06 - 6.09
Close: 6.43 - 6.49 6.49 - 6.54

Company Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Headline News

Mon, 22 May 2023
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur - Yahoo Finance

Sun, 21 May 2023
Tocqueville Asset Management Decreases Stake in DURECT Co ... - Best Stocks

Mon, 08 May 2023
DURECT Corporation Reports First Quarter 2023 Financial Results ... - PR Newswire

Mon, 01 May 2023
DURECT Corporation to Announce First Quarter 2023 Financial ... - PR Newswire

Thu, 27 Apr 2023
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis - Yahoo Finance

Tue, 11 Apr 2023
HC Wainwright & Co. Reiterates DURECT (DRRX) Buy ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 24 (M)
Shares Float 19 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 39.5 (%)
Shares Short 362 (K)
Shares Short P.Month 424 (K)

Stock Financials

EPS -2.1
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.64
Profit Margin (%) -187.9
Operating Margin (%) -184.1
Return on Assets (ttm) -32.2
Return on Equity (ttm) -116
Qtrly Rev. Growth 7.3
Gross Profit (p.s.) 0.67
Sales Per Share 0.79
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -3.05
PEG Ratio -0.3
Price to Book value 9.83
Price to Sales 8.05
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.